AbbVie Highlights Durable IBD Data at UEGW 2026, Potential Upside for SKYRIZI and RINVOQ
Oct 17, 2026, 2:11 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Durable remission and rapid response signals across multiple IBD indications, plus real-world evidence and a regulatory submission, tend to support multiple-year revenue visibility and could lift sentiment and multiple expansion near term. Historically, positive phase-long data and regulatory milestones in GI have led to short- to mid-term stock moves for AbbVie and peers when coupled with a clear path to label expansion.
AI summary
What happened, with direct paths to the underlying reporting
AbbVie disclosed 20 abstracts at UEG Week 2026, detailing long-term and real-world IBD results for SKYRIZI and RINVOQ, plus early signals from ABBV-466. Durable remission and rapid response data across UC and CD support the franchise's growth trajectory, with regulatory momentum including an EMA submission for SKYRIZI induction in Crohn's. These findings could bolster sentiment and long-term revenue visibility.
AbbVie cites 20 abstracts at UEG Week 2026 across SKYRIZI, RINVOQ, and ABBV-466.
Upadacitinib CD outcomes through week 144 show remission 78.9%-86.6%; endoscopic remission 47.1%-64.2%.
Real-world data (UPlift): 70.2% of evaluable Crohn's patients responded within 12 weeks.
ABBV-466 demonstrates endoscopic remission in Phase 2a TARGET-CD for Crohn's disease.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
AbbVie disclosed that the FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan, signaling accelerated development potential for a key oncology candidate.…
Genmab and AbbVie reported positive late-stage results for a lymphoma combo in newly diagnosed patients, reducing the risk of progression or death. The findings bolster AbbVie's o…
AbbVie’s FDA approval of JUVMO for Parkinson’s disease introduces a new growth catalyst to its portfolio, potentially expanding revenue and pipeline value. The initial market reac…
AbbVie won FDA approval for Juvmo (tavapadon), a selective D1/D5 receptor agonist for Parkinson’s, and plans a U.S. launch in October 2026. The TEMPO Phase 3 program supported its…
